- University of St. Gallen (M.A. HSG in Law and Economics, 2013) - University of Lausanne (2012)

Transcription

1 Luzius Zumstein M.A. HSG in Law and Economics Attorney at Law Associate Languages: German, English, French Contact: , General Luzius Zumstein is an Attorney in the Corporate Team. His primary practice areas are corporate and commercial law, mergers & acquisitions and private equity. He has specific expertise in compliance matters, especially in the implementation of anti-corruption measures in international companies, and in employment law. Education - University of St. Gallen (M.A. HSG in Law and Economics, 2013) - University of Lausanne (2012) Teams Compliance Support, Corporate and Commercial, Employment Law, Life Sciences, Pharma, Biotech, Listed Companies, Mergers & Acquisitions, Private Equity, Venture Capital, Corporate Finance, Startup Desk, White Collar Crime 1/6

2 Practice Areas Biotechnology Law, Commercial Law, Compliance Support, Corporate and Commercial, Employment, Financing, Life Sciences, M&A, Pharma, Private Equity, Venture Capital, White Collar Crime Deals Lundbeck to acquire Prexton Therapeutics H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay EUR 100m upfront and is furthermore required to later pay up to EUR 805m in development and sales milestones to the group of current owners. VISCHER advised Lundbeck as lead-counsel in this transaction. The team was led by Corporate partners Christian Wyss and Robert Bernet and included Luzius Zumstein, Gian Caprez, Gian Geel, Aron Waltuch (all Corporate), Marc Prinz (Employment) and Eric Flückiger (Tax). Oculis CHF 20m Financing Round Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced the completion of a CHF 20m Series B financing. The round involved a syndicate of leading transatlantic life sciences investors composed of Novartis Venture Fund, Pivotal bioventure Partners and Bay City Capital as well as existing investors including Brunnur Ventures and Silfurberg. In connection with this financing, Oculis is relocating its corporate headquarters to Lausanne, Switzerland, while keeping its R&D activities in Reykjavik, Iceland. VISCHER acted as counsel to the new investors with respect to the financing and assisted Oculis with its relocation to Switzerland. The team was led by Dr. Matthias Staehelin (Partner, Corporate) and Nadia Tarolli (Partner, Tax) with the support of Vincent S. Reardon (Senior Associate, Corporate), Luzius Zumstein (Associate, Corporate) and Adrian Briner (Associate, Tax). ImmunOs Therapeutics AG closes CHF 2.3m Financing Round ImmunOs Therapeutics AG, a Swiss bio-technology company leading development of a next generation innate and adaptive immunity focused immunotherapy platform for cancer, announced the closing of its 2.3 Million CHF financing round. The proceeds of the financing will be used to advance its lead clinical candidate, a single multitasking protein agent, for treating solid tumors. VISCHER acted as counsel to ImmunOs. The team was led by Christian Wyss (Partner) and supported by Luzius Zumstein (Associate), both Corporate. NOUSCOM EUR 42m Financing Round NOUSCOM, an oncology company developing neoantigen based cancer vaccines, announced the completion of a EUR 42m Series B financing. The round involved a syndicate of leading transatlantic life sciences investors led by new investors Abingworth with participation from 5AM Ventures and the existing investors LSP and Versant Ventures. VISCHER acted as counsel to NOUSCOM. The team was led by Dr. Matthias Staehelin (Partner) and supported by Luzius Zumstein (Associate), both Corporate. TOLREMO therapeutics AG raises CHF 2.4 million in seed financing round TOLREMO therapeutics AG, a privately held research-stage biotechnology company, announced the completion of a financing round with private 2/6

3 investors in the amount of CHF 2.4 m. The proceeds will be used to advance the company s discovery and development of breakthrough medicines to target drug resistance in cancer therapy. VISCHER advised TOLREMO in this financing round. The VISCHER team includes Dr. Matthias Staehelin (Partner) and Luzius Zumstein (Associate), both Corporate. Balderton Capital invests in Sophia Genetics USD 30m series D round Balderton Capital, a London-based venture capital fund with a focus on ambitious entrepreneurs, disruptive technology and sustainable businesses, led the series D financing round over USD 30m in Sophia Genetics SA, one of the world s foremost companies in the field of applying artificial intelligence to genomic analysis. VISCHER acted as transaction counsel to Balderton Capital. The team was led by Christian Wyss (Partner) and supported by Luzius Zumstein (Associate) and Aron Waltuch (Trainee), all Corporate. Polyphor Ltd Financing Round Polyphor Ltd, a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 m private placement. Existing Polyphor investors, including the anchor investors Varuma AG and Ingro Finanz AG, contributed to 98% of the financing. VISCHER assisted Polyphor in this transaction. The team at VISCHER was led by Matthias Staehelin with Luzius Zumstein (both Corporate). Baloise acquires around 70 per cent of Pax Anlage AG The purchases announced on 6 January 2017 by Baloise Life Ltd, a subsidiary of Bâloise Holding Ltd, of three blocks of shares amounting to around 70 per cent of the share capital and voting rights of Pax Anlage AG from Pax Holding (cooperative), PAX, Schweizerische Lebensversicherungs-Gesellschaft AG and Nürnberger Lebensversicherung AG, were completed on 31 March The necessary official approvals for the transaction were issued on 9 February 2017 (by the Swiss Financial Market Supervisory Authority, FINMA) and 2 March 2017 (by the Swiss Competition Commission, WEKO). On 10 March 2017, Baloise published its offer prospectus for the public tender offer for all publicly held registered shares in Pax Anlage. VISCHER advises Baloise. The VISCHER team is led by Partner Benedict F. Christ and included Dr. Peter Kühn (Managing Associate) and Luzius Zumstein (Associate) all corporate/m&a and Klaus Neff (Partner) antitrust. Partnership of Anokion with Celgene Anokion located in Lausanne and Celgene Corp. (NASDAQ:CELG) partnered to use Anokion's biotech immune tolerizing platform to develop therapies for autoimmune diseases. Anokion received a $45 m upfront payment and is eligible to receive a future payment of an additional $10 m based on certain preclinical development achievements. As part of the strategic collaboration agreement, Celgene obtained an equity interest in Anokion and the exclusive right to acquire Anokion at pre-specified option exercise points. Anokion s most advanced approach to immune tolerance harnesses the body s natural tolerance mechanism of apoptotic or aging cells. It involves engineering antigens, relevant to a broad range of autoimmune disorders, to bind glycophorin A, a surface protein unique to erythrocytes or red blood cells. VISCHER (together with Skadden, Arps, Slate, Meagher & Flom LLP) have been advising Anokion in this transaction. The team at VISCHER was led by Dr. Matthias Staehelin (Partner, Corporate) and Nadia Tarolli (Partner, Tax) with Vincent Reardon and Luzius Zumstein (both Associates, Corporate). Baloise is to acquire Pax Anlage AG and boosts its real-estate portfolio Baloise is to acquire a majority shareholding in Pax Anlage AG and to make a 3/6

4 public takeover offer for the remaining shares. This transaction represents a further expansion of Baloise's real-estate portfolio and Baloise thereby invests up to CHF 288 million of insurance assets in a secure and attractive asset class. The transaction is subject to governmental approvals. VISCHER advises Baloise. The VISCHER team is led by partner Benedict F. Christ and included Peter Kühn, Vincent Reardon, Seraina Tsering, Dominic Wyss und Luzius Zumstein (corporate/m&a), Roland Müller, Peter Hettich, Manuel Blättler, Moritz Jäggy, Rebekka Keller, Reto Marghitola, Elias Mühlemann (real estate), Klaus Neff (anti-trust) and Delia Bosshard (IP). Series B Investment in NBE Therapeutics NBE Therapeutics, a company developing next-generation antibody-drug conjugates (ADCs), recently announced the closing of a CHF 20 m Series B financing round and a collaboration with SOTIO a.s. for the discovery, nonclinical development and manufacturing of novel ADC products. As part of the deal, the PPF Group has committed to invest CHF 10 m in NBE. VISCHER has been advising the PPF Group in the financing transaction. The team was led by Matthias Staehelin (Corporate) with Dania Salvisberg-Schneider (Corporate) and Luzius Zumstein (Corporate). IPO of CRISPR Therapeutics at NASDAQ CRISPR Therapeutics AG (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, announced on October 18, 2016 the pricing of its initial public offering of 4'000'000 common shares at a public offering price of $14.00 per share. CRISPR Therapeutics common shares have started trading on the NASDAQ Global Market under the ticker symbol "CRSP" on October 19, Citigroup, Piper Jaffray and Barclays acted as joint book-running managers for the offering. Guggenheim Securities acted as co-manager. In addition to the shares sold in the public offering, CRISPR Therapeutics also completed the concurrent sale of an additional 2'500'000 shares at the initial offering price of $14.00, for gross proceeds of $35.0 million, in a private placement to Bayer Global Investments B.V., an existing shareholder and an affiliate of Bayer HealthCare LLC, a joint venture partner with CRISPR Therapeutics. VISCHER AG and Goodwin Procter LLP are legal advisors to the Company. The team at VISCHER is led by Matthias Staehelin (Partner Corporate) with Stefan Grieder (Partner Corporate), Nadia Tarolli (Partner Tax), Angelo Imperiale, Gian Caprez, Vincent Reardon and Luzius Zumstein (all Associates). ABBA Therapeutics enters into OmniAB Platform License Agreement ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) have entered into a worldwide license agreement. Under the license, ABBA Therapeutics AG will be able to use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human monoand bispecific antibodies. VISCHER advised ABBA Therapeutics AG in the negotiations. The VISCHER team includes partner Christian Wyss and Luzius Zumstein. Swissmem invests in AM-Tec Swissmem, the association of around 1000 companies in the Swiss mechanical and electrical engineering industries and associated technologyoriented sectors, has invested in AM-Tec Kredit AG, which provides established SMEs with capital to fund growth and innovation. With this investment Swissmem is indirectly expanding the range of services it provides to the Swiss industry. VISCHER is advising Swissmem on this investment. The VISCHER team for this transaction consists of Robert Bernet (Partner Corporate/M & A), Peter Kühn, Marius Meier (both Senior Associates Corporate/M & A) and Lucius Zumstein (Junior Associate). 4/6

5 Practice - Legal internship at the Civil Court of Basel-City - Legal internship at VISCHER - Internship at the legal department of an international pharmaceutical firm Memberships in Associations - Basel Bar Association - Swiss Bar Association - International Bar Association 5/6

6 About VISCHER We effectively support our clients in a solution oriented manner in legal, tax and regulatory matters. Our lawyers, tax experts and notaries are organized in the specialist practice teams listed below, each led by an experienced partner. This enables us to individually tailor our services to meet the requirements of the individual project in the most effective manner. Our offices are located in Zurich and Basel, the two largest business centers of Switzerland. Independence is a key factor for the optimal protection of client interests. We therefore put great value on a very high conflict of interest standard that is no longer obvious in the international legal industry. In order to also remain independent in transborder transactions, we have built up our own global network of foreign law firms enabling us to select our foreign attorneys based exclusively on the requirements of the individual mandates and without having to take into consideration the instructions of a law firm group or a network organization. - Antitrust and Competition - Aviation - Banking and Finance - China Desk - Civil Law Notaries - Compliance Support - Corporate and Commercial - Data & Privacy - Employment Law - Energy - Health Care - Immigration - Information and Communication Technology - Intellectual Property - Life Sciences, Pharma, Biotech - Listed Companies - Litigation, Arbitration - Media and Entertainment - Mergers & Acquisitions - Pension Funds - Private Clients - Private Equity, Venture Capital, Corporate Finance - Public Sector and Regulatory - Real Estate - Restructuring and Insolvency - Sports Law - Startup Desk - Tax - White Collar Crime Zürich VISCHER AG Schützengasse Zürich Switzerland Tel Basel VISCHER AG Aeschenvorstadt Basel Switzerland Tel /6